KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to -$42.6 million.

  • Alnylam Pharmaceuticals' Free Cash Flow rose 692.02% to $313.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.4 million, marking a year-over-year increase of 1278.10%. This contributed to the annual value of -$42.6 million for FY2024, which is 201.54% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Free Cash Flow of -$42.6 million as of FY2024, which was down 201.54% from $41.9 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Free Cash Flow registered a high of $41.9 million during FY2023, and its lowest value of -$718.1 million during FY2021.
  • In the last 3 years, Alnylam Pharmaceuticals' Free Cash Flow had a median value of -$42.6 million in 2024 and averaged -$204.7 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Free Cash Flow skyrocketed by 106.84% in 2023 and then slumped by 201.54% in 2024.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Free Cash Flow stood at -$685.3 million in 2020, then decreased by 4.78% to -$718.1 million in 2021, then rose by 14.59% to -$613.3 million in 2022, then soared by 106.84% to $41.9 million in 2023, then tumbled by 201.54% to -$42.6 million in 2024.